ROCKet Trial officially commenced today with recruitment of the first patient at Austin Health.
Reduction Of Chronic Post-surgical Pain with Ketamine Trial is a 5-year, 4,884 patient, multicentre, double-blind, placebo controlled, phase 3/4 randomised controlled trial of the effect of up to 72 hours of perioperative ketamine on the risk of development of chronic post-surgical pain (CPSP).
The trial will be managed by the University of Melbourne Medical School’s Anaesthesia, Perioperative and Pain Medicine Unit, of which co-investigator Professor David Story is the Head.
The investigators have incorporated biostatistics and health economics expertise provided by the faculty’s Melbourne Clinical and Translational Science Platform (MCATS). Co-investigators include Professor Kate Leslie (University of Melbourne), Professor Paul Myles (Monash University), Doctor Matthew Chan (The Chinese University of Hong Kong), Professor Stephan Schug (University of Western Australia), Associate Professor Lisbeth Evered (University of Melbourne), and Miss Sabine Braat (University of Melbourne).
Visit the ROCKet Trial UniMelb website for further information on the study and to express interest in joining.
About the Chief Investigator###
Professor Philip Peyton is a clinician researcher and Austin Health's Director of Anaesthesia Research. His research interests includes anaesthetic physiology and pharamacology and he has published over 100 publications. He has been a Chief Investigator in several large multicentre international clinical trials in anaesthesia.
Read more about his research here:
- Does perioperative ketamine have a role in the prevention of chronic postsurgical pain: the ROCKet trial on SAGE Journals
- Visit University of Melbourne profile
- View publications on SciTitles